ReviewMedical hypothesis, discovery & innovation ophthalmology journal2016
Topical Atropine in the Control of Myopia.
Review in Medical hypothesis, discovery & innovation ophthalmology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: A meta-analysis.PloS one · 2023Pooled it
- Navigating the Core Challenges of Atropine Therapy in Myopia: A Mechanistic and Clinical Analysis of Dose, Response, and Durability.Journal of ophthalmology · 2026Review
- Microbial and Chemical Stability of Unpreserved Atropine Sulfate 0.01%Life (Basel, Switzerland) · 2025Article
- IMI-Interventions for Controlling Myopia Onset and Progression 2025.Investigative ophthalmology & visual science · 2025Review
- Low concentration atropine and myopia: a narrative review of the evidence for United Kingdom based practitioners.Eye (London, England) · 2024Review
- The Preventive Role of Atropine Eye Drops on Myopia Progression: A Double-Blind Randomized Clinical Trial.International journal of preventive medicine · 2023Article
- Candidate pathways for retina to scleral signaling in refractive eye growth.Experimental eye research · 2022Review
- Short-term effect of atropine on higher-order aberrations in myopic children.Journal of the Chinese Medical Association : JCMA · 2021Article
- The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children.Journal of clinical medicine · 2021Article
- Corneal Penetration of Low-Dose Atropine Eye Drops.Journal of clinical medicine · 2021Article
- Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atropine has been used for more than a century to arrest myopia progression. Compelling evidence of its protective effect has been reported in well-designed clinical studies, mainly performed during the last two decades. However, its exact mechanism of action has not been determined. Experimental findings have shown that the mechanism is not related to accommodation, as was thought for decades. A review of the published literature revealed a significant amount of evidence supporting its safety and efficacy at a concentration of 1.0%, and at lower concentrations (as low as 0.01%).
Indexed as
Identifiers
28293653PMC5347209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.